BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33139817)

  • 21. Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population.
    Ancot F; Arcand SL; Mes-Masson AM; Provencher DM; Tonin PN
    Oncol Lett; 2015 Jun; 9(6):2787-2790. PubMed ID: 26137147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
    J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
    Friedman E; Kotsopoulos J; Lubinski J; Lynch HT; Ghadirian P; Neuhausen SL; Isaacs C; Weber B; Foulkes WD; Moller P; Rosen B; Kim-Sing C; Gershoni-Baruch R; Ainsworth P; Daly M; Tung N; Eisen A; Olopade OI; Karlan B; Saal HM; Garber JE; Rennert G; Gilchrist D; Eng C; Offit K; Osborne M; Sun P; Narod SA;
    Breast Cancer Res; 2006; 8(2):R15. PubMed ID: 16563180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Publisher Correction: Breast cancer drug approvals by the US FDA from 1949 to 2018.
    Leo CP; Leo C; Szucs TD
    Nat Rev Drug Discov; 2020 Apr; 19(4):291. PubMed ID: 31937949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
    N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reproductive factors in hereditary breast cancer.
    Jernström HC; Johannsson OT; Loman N; Borg A; Olsson H
    Breast Cancer Res Treat; 1999 Dec; 58(3):295-301. PubMed ID: 10718491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
    Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
    Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
    Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
    Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study.
    Couch FJ; Sinilnikova O; Vierkant RA; Pankratz VS; Fredericksen ZS; Stoppa-Lyonnet D; Coupier I; Hughes D; Hardouin A; Berthet P; Peock S; Cook M; Baynes C; Hodgson S; Morrison PJ; Porteous ME; Jakubowska A; Lubinski J; Gronwald J; Spurdle AB; ; Schmutzler R; Versmold B; Engel C; Meindl A; Sutter C; Horst J; Schaefer D; Offit K; Kirchhoff T; Andrulis IL; Ilyushik E; Glendon G; Devilee P; Vreeswijk MP; Vasen HF; Borg A; Backenhorn K; Struewing JP; Greene MH; Neuhausen SL; Rebbeck TR; Nathanson K; Domchek S; Wagner T; Garber JE; Szabo C; Zikan M; Foretova L; Olson JE; Sellers TA; Lindor N; Nevanlinna H; Tommiska J; Aittomaki K; Hamann U; Rashid MU; Torres D; Simard J; Durocher F; Guenard F; Lynch HT; Isaacs C; Weitzel J; Olopade OI; Narod S; Daly MB; Godwin AK; Tomlinson G; Easton DF; Chenevix-Trench G; Antoniou AC;
    Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1416-21. PubMed ID: 17627006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.
    Cui J; Antoniou AC; Dite GS; Southey MC; Venter DJ; Easton DF; Giles GG; McCredie MR; Hopper JL
    Am J Hum Genet; 2001 Feb; 68(2):420-31. PubMed ID: 11133358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
    Claus EB; Petruzella S; Matloff E; Carter D
    JAMA; 2005 Feb; 293(8):964-9. PubMed ID: 15728167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
    Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Narod SA; Dubé MP; Klijn J; Lubinski J; Lynch HT; Ghadirian P; Provencher D; Heimdal K; Moller P; Robson M; Offit K; Isaacs C; Weber B; Friedman E; Gershoni-Baruch R; Rennert G; Pasini B; Wagner T; Daly M; Garber JE; Neuhausen SL; Ainsworth P; Olsson H; Evans G; Osborne M; Couch F; Foulkes WD; Warner E; Kim-Sing C; Olopade O; Tung N; Saal HM; Weitzel J; Merajver S; Gauthier-Villars M; Jernstrom H; Sun P; Brunet JS
    J Natl Cancer Inst; 2002 Dec; 94(23):1773-9. PubMed ID: 12464649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications.
    McClain MR; Palomaki GE; Nathanson KL; Haddow JE
    Genet Med; 2005 Jan; 7(1):28-33. PubMed ID: 15654225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
    Kolben T; Hary T; Holdt LM; Schwarz TM; Goess C; Wuerstlein R; Gallwas J; Toth B; Weissenbacher T; Jeschke U; Harbeck N; Ditsch N
    Anticancer Res; 2016 Jun; 36(6):3185-90. PubMed ID: 27272846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.